Dimensional Fund Advisors LP Increases Stock Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Dimensional Fund Advisors LP boosted its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 1.6% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 1,239,502 shares of the medical equipment provider’s stock after acquiring an additional 19,071 shares during the quarter. Dimensional Fund Advisors LP owned 1.79% of Lantheus worth $99,525,000 as of its most recent filing with the SEC.

Other large investors also recently added to or reduced their stakes in the company. UMB Bank n.a. increased its stake in shares of Lantheus by 161.4% during the first quarter. UMB Bank n.a. now owns 400 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 247 shares in the last quarter. GAMMA Investing LLC increased its stake in Lantheus by 184.1% during the 2nd quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 208 shares in the last quarter. Principal Securities Inc. acquired a new position in shares of Lantheus during the fourth quarter valued at approximately $28,000. Fidelis Capital Partners LLC purchased a new position in shares of Lantheus in the first quarter valued at approximately $34,000. Finally, FinTrust Capital Advisors LLC boosted its stake in shares of Lantheus by 53.6% in the first quarter. FinTrust Capital Advisors LLC now owns 665 shares of the medical equipment provider’s stock worth $41,000 after acquiring an additional 232 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Redburn Atlantic started coverage on shares of Lantheus in a research note on Tuesday, September 3rd. They set a “buy” rating and a $175.00 target price on the stock. JMP Securities dropped their price objective on shares of Lantheus from $130.00 to $125.00 and set a “market outperform” rating for the company in a research note on Thursday, August 1st. Leerink Partners raised their target price on shares of Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a research note on Thursday, July 11th. Truist Financial dropped their price target on Lantheus from $141.00 to $135.00 and set a “buy” rating for the company in a research report on Thursday, August 1st. Finally, B. Riley lifted their price objective on Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $126.00.

Insider Buying and Selling at Lantheus

In other news, Director Gary J. Pruden sold 12,530 shares of the firm’s stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $95.04, for a total transaction of $1,190,851.20. Following the completion of the transaction, the director now directly owns 11,978 shares in the company, valued at $1,138,389.12. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other news, Director Gary J. Pruden sold 12,530 shares of the stock in a transaction dated Wednesday, July 10th. The shares were sold at an average price of $95.04, for a total transaction of $1,190,851.20. Following the sale, the director now owns 11,978 shares of the company’s stock, valued at $1,138,389.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gerard Ber sold 15,500 shares of Lantheus stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the completion of the transaction, the director now owns 21,221 shares of the company’s stock, valued at approximately $2,047,402.08. The disclosure for this sale can be found here. Insiders have sold a total of 40,852 shares of company stock valued at $3,922,001 over the last quarter. 1.50% of the stock is owned by company insiders.

Lantheus Stock Performance

Shares of Lantheus stock opened at $111.76 on Wednesday. The firm has a market cap of $7.75 billion, a PE ratio of 17.06 and a beta of 0.50. The company has a quick ratio of 4.41, a current ratio of 4.68 and a debt-to-equity ratio of 0.55. Lantheus Holdings, Inc. has a 52 week low of $50.20 and a 52 week high of $126.89. The business’s fifty day simple moving average is $105.14 and its 200-day simple moving average is $85.08.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share for the quarter, missing the consensus estimate of $1.68 by ($0.07). The company had revenue of $394.10 million for the quarter, compared to analysts’ expectations of $382.12 million. Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The company’s quarterly revenue was up 22.5% compared to the same quarter last year. During the same period last year, the business earned $1.40 EPS. Equities analysts forecast that Lantheus Holdings, Inc. will post 5.99 earnings per share for the current year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.